Company Profile

Acumen Pharmaceuticals Inc
Profile last edited on: 10/9/2023      CAGE: 482E3      UEI: YHM4FW9X3YC3

Business Identifier: Therapeutics and diagnostics for Alzheimer’s disease
Year Founded
1996
First Award
2005
Latest Award
2016
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

427 Park Street
Charlottesville, VA 22902
   (229) 02-
   info@acumenpharm.com
   www.acumenpharm.com
Location: Single
Congr. District: 15
County: Charlottesville city

Public Profile

Acumen is organized around development of effective therapeutics and diagnostics for treating Alzheimer’s disease and related neurodegenerative conditions. With the focus on disease-modifying drugs that block and reverse memory loss in Alzheimer’s, Acumen is focused on developing ADDL-Select™ antibodies that target soluble A? oligomers, which are now widely recognized as a key culprit in the disease process through their ability to inhibit nerve function, trigger early memory deficits and initiate nerve cell degeneration and downstream pathological events in Alzheimer’s. Acumen’s founders discovered synthetic soluble A? oligomers, called ADDLs for A?-Derived Diffusible Ligands to distinguish them from insoluble A? plaques. Acumen’s founders also pioneered the study of soluble A? oligomers and their pathological role in Alzheimer’s disease. Acumen owns or controls dominant intellectual property regarding ADDLs, soluble A? oligomers and related therapeutics and diagnostics.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
25-49
Revenue Range
2.5M-5M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : ABOS
IP Holdings
10-14

Awards Distribution by Agency

Key People / Management

  Daniel O'Connell -- President & CEO

  Caleb E Finch -- Co-Founder and Member of Scientific Advisory Board

  William F Goure -- Chief Operating Office

  Franz F Hefti -- Director

  William L Klein

  Grant A Krafft -- Chairman, Co-Founder, Chief Science Advisor

  Matt Zuga -- CFO & Chief Bus. Officer